Cancer Letters
Volume 226, Issue 1 , Pages 37-47 , 8 August 2005

Antitumor effect of gefitinib (‘Iressa’) on esophageal squamous cell carcinoma cell lines in vitro and in vivo

Received 19 August 2004 ,Revised 13 December 2004 ,Accepted 15 December 2004.

References 

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer. 2001;94:153–156
  2. Kuwano H, Sadanaga N, Watanabe M, Yasuda M, Nozoe T, Sugimachi K. Oesophageal cancer composed of mixed histological types. Eur. J. Surg. Oncol. 1996;22:225–231
  3. Lerut T, Coosemans W, Leyn PD, Raemdonck DV, Deneffe G, Decker G. Treatment of esophageal carcinoma. Chest. 1999;116(Suppl. 6):463S–465S
  4. Koshy M, Esiashvilli N, Landry JC, Thomas CR, Matthews RH. Multiple management modalities in esophageal cancer: combined modality management approaches. Oncologist. 2004;9:147–159
  5. Cohen S, Carpenter G, King L. Epidermal growth factor-receptor-protein kinase interactions, co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J. Biol. Chem. 1980;255:4834–4842
  6. Hynes NE, Horsch K, Olayioye MA, Badache A. The ErbB receptor tyrosine family as signal integrators. Endocr. Relat. Cancer. 2001;8:151–159
  7. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103:211–215
  8. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat. Rev. Mol. Cell. Biol. 2001;2:127–137
  9. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 2000;6:4885–4892
  10. Ciardiello F, Caputo R, Borriello G, Bufalo DD, Biroccio A, Zupi G, et al. ZD1839 (Iressa), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug resistant MCF-7ADR human breast cancer cells. Int. J. Cancer. 2002;98:463–469
  11. Bianco C, Tortora G, Bianco R, Caputo R, Veneziani BM, Capto R, et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa). Clin. Cancer Res. 2002;8:3250–3258
  12. Janne PA, Taffaro ML, Salgia R, Johnson BE. Inhibition of epidermal growth factor receptor signaling in malignant pleural methothelioma. Cancer Res. 2002;62:5242–5247
  13. Iihara K, Shiozaki H, Tahara H, Kobayashi K, Inoue M, Tamura S, et al. Prognostic significance of transforming growth factor-alpha in human esophageal carcinoma. Implication for the autocrine proliferation. Cancer. 1993;71:2902–2909
  14. Ozawa S, Ueda M, Ando N, Abe O, Shimizu N. High incidence of EGF receptor hyperproduction in esophageal squamous-cell carcinomas. Int. J. Cancer. 1987;39:333–337
  15. Ozawa S, Ueda M, Ando N, Shimizu N, Abe O. Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas. Cancer. 1989;63:2169–2173
  16. Shimada Y, Imamura M, Watanabe G, Uchida S, Harada H, Makino T, et al. Prognostic factor of oesophageal squamous cell carcinoma from the perspective of molecular biology. Br. J. Cancer. 1999;80:1281–1288
  17. Kitagawa Y, Ueda M, Ando N, Ozawa S, Shimizu N, Kitajima M. Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin. Cancer Res. 1996;2:909–914
  18. Ozawa S, Ueda M, Ando N, Shimizu N, Abe O. Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas. Cancer. 1989;63:2169–2173
  19. Itakura Y, Sasano H, Shiga C, Furukawa Y, Shiga K, Mori S, et al. Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer. 1994;74:795–804
  20. Hickey K, Grehan D, Reid IM, O'Braiain S, Walsh TN, Hennessy TP. Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemotherapy. Cancer. 1994;74:1693–1698
  21. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD, Morse D, et al. United States Food and Drug Administration Drug Approval summary: gefitinib (ZD1839; Iressa) tablets. Clin. Cancer Res. 2004;10:1212–1218
  22. Nakagawa K, Tamura T, Negoro S, Kudoh S, Yamamoto N, Yamamoto N, et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (’Iressa’, ZD1839) in Japanese patients with solid malignant tumors. Ann. Oncol. 2003;14:922–930
  23. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2003;21:2237–2246
  24. Jacquemier JD, Penault-Llorca FM, Bertucci F, Sun ZZ, Houvenaeghel GF, Geneix JA, et al. Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: a multiparametric and immunohistochemical analysis. J. Pathol. 1998;184:130–135
  25. Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, Kinoshita H, et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol. Cancer Ther. 2004;3:465–472
  26. Shintani S, Li C, Mihara M, Yano J, Terakado N, Nakashiro K, et al. Gefitinib (’Iressa’, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up-regulates p27KIP1 and induces G1 arrest in oral squamous cell carcinoma cell lines. Oral Oncol. 2004;40:43–51
  27. Gennaro ED, Barbarino M, Bruzzese F, Lorenzo SD, Caraglia M, Abbruzzese A, et al. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 (’Iressa’), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. J. Cell. Physiol. 2003;195:139–150
  28. Li B, Chang CM, Yuan M, McKenna WG, Shu HK. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res. 2003;63:7443–7450
  29. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin. Cancer Res. 2003;9:2316–2326
  30. She QB, Solit D, Basso A, Moasser MM. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin. Cancer Res. 2003;9:4340–4346
  31. Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 2000;60:2926–2935
  32. Hirata A, Ogawa S, Kometani T, Kuwano T, Naito S, Kuwano M. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res. 2002;62:2554–2560
  33. Magne N, Fischel JL, Dubreuil A, Formento P, Poupon MF, Puig PL, et al. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (“Iressa”). Br. J. Cancer. 2002;86:1518–1523
  34. Suzuki T, Nakagawa T, Endo H, Mitsudomi T, Masuda A, Yatabe Y, et al. The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 (’Iressa’) is not related to the expression of EGFR or HER-2 or to K-ras gene status. Lung Cancer. 2003;42:35–41
  35. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, Placido SD, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 2000;6:2053–2063
  36. Perez-Soler R. The role of erlotinib (Tarceva OSI 774) in the treatment of non-small cell lung cancer. Clin. Cancer Res. 2004;15:4238s–4240s
  37. Campiglio M, Locatelli A, Olgiati C, Normanno N, Somenzi G, Vigano L. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (’Iressa’) is independent of EGFR expression level. J. Cell. Physiol. 2004;198:259–268
  38. Anido J, Matar P, Albanell J, Guzman M, Rojo F, Arribas J. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin. Cancer Res. 2003;9:1274–1283
  39. Wang Y, Chen J, Meng L, Liu J, Du D, Zou Y. A histopathologic and immunohistochemical study of prognostic factors in esophageal squamous cell carcinoma. Zhonghua Bing Li Xue Za Zhi. 2000;29:267–271
  40. Akamatsu M, Matsumoto T, Oka K, Yamasaki S, Sonoue H, Kajiyama Y. c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2003;57:1323–1327

PII: S0304-3835(04)00997-8

doi: 10.1016/j.canlet.2004.12.025

Cancer Letters
Volume 226, Issue 1 , Pages 37-47 , 8 August 2005

Article Tools

* Image Usage & Resolution